DB:B002

Stock Analysis Report

Executive Summary

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample.

Snowflake

Fundamentals

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Biocept's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: B002's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-16.2%

B002

5.5%

DE Biotechs

-0.3%

DE Market


1 Year Return

-63.4%

B002

-1.9%

DE Biotechs

10.9%

DE Market

Return vs Industry: B002 underperformed the German Biotechs industry which returned -1.9% over the past year.

Return vs Market: B002 underperformed the German Market which returned 10.9% over the past year.


Shareholder returns

B002IndustryMarket
7 Day-16.2%5.5%-0.3%
30 Day-26.3%-0.8%2.6%
90 Day-44.7%-4.8%11.8%
1 Year-63.4%-63.4%-1.6%-1.9%14.4%10.9%
3 Yearn/a65.5%63.4%24.1%13.2%
5 Yearn/a7.2%4.8%33.0%14.8%

Price Volatility Vs. Market

How volatile is Biocept's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Biocept undervalued compared to its fair value and its price relative to the market?

1.58x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate B002's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate B002's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: B002 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: B002 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate B002's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: B002 is good value based on its PB Ratio (1.6x) compared to the DE Biotechs industry average (3.1x).


Next Steps

Future Growth

How is Biocept forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

30.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: B002 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: B002 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: B002 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: B002's revenue (58% per year) is forecast to grow faster than the German market (4.8% per year).

High Growth Revenue: B002's revenue (58% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if B002's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Biocept performed over the past 5 years?

-12.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: B002 has high quality earnings.

Growing Profit Margin: B002 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: B002 is unprofitable, and losses have increased over the past 5 years at a rate of -12.4% per year.

Accelerating Growth: Unable to compare B002's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: B002 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: B002 has a negative Return on Equity (-330.13%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Biocept's financial position?


Financial Position Analysis

Short Term Liabilities: B002's short term assets ($10.6M) exceeds its short term liabilities ($5.8M)

Long Term Liabilities: B002's short term assets ($10.6M) exceeds its long term liabilities (1.0M)


Debt to Equity History and Analysis

Debt Level: B002 is debt free.

Reducing Debt: B002 has no debt compared to 5 years ago when its debt to equity ratio was 147.2%.


Balance Sheet

Inventory Level: B002 has a high level of physical assets or inventory.

Debt Coverage by Assets: B002's debt is not covered by short term assets (assets are 79.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: B002 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: B002 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.8% each year


Next Steps

Dividend

What is Biocept's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate B002's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate B002's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if B002's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if B002's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of B002's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Biocept's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Mike Nall (56yo)

6.3yrs

Tenure

US$439,720

Compensation

Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has over 30 years of leadership experience in healthcare sales,  ...


CEO Compensation Analysis

Compensation vs Market: Mike's total compensation ($USD439.72K) is above average for companies of similar size in the German market ($USD216.03K).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.3yrs

Average Tenure

61yo

Average Age

Experienced Management: B002's management team is considered experienced (3.3 years average tenure).


Board Age and Tenure

8.6yrs

Average Tenure

71yo

Average Age

Experienced Board: B002's board of directors are considered experienced (8.6 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 615.8%.


Management Team

  • Soon Kap Hahn

    • Tenure: 22.8yrs
  • Mike Terry (64yo)

    Senior Vice President of Corporate Development

    • Tenure: 0yrs
  • Lyle Arnold (72yo)

    Senior VP of R&D

    • Tenure: 0yrs
    • Compensation: US$287.43k
  • David Moskowitz

    Vice President of Strategy & Corporate Communications

    • Tenure: 3.1yrs
  • Michael Brown

    General Counsel and Compliance & Privacy Officer

    • Tenure: 2.1yrs
  • Tim Kennedy (61yo)

    CFO, Senior VP of Operations & Corporate Secretary

    • Tenure: 3.3yrs
    • Compensation: US$359.04k
  • Pavel Tsinberg

    Director of Technology Development

    • Tenure: 2.2yrs
  • Mike Nall (56yo)

    CEO, President & Director

    • Tenure: 6.3yrs
    • Compensation: US$439.72k
  • Veena Singh (44yo)

    Senior Medical Director

    • Tenure: 4.9yrs
    • Compensation: US$115.22k
  • Cory Dunn

    Vice President of Marketing

    • Tenure: 1yrs

Board Members

  • M. Wilson (81yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$56.16k
  • Ivor Royston (73yo)

    Independent Director

    • Tenure: 9.8yrs
    • Compensation: US$41.16k
  • David Hale (70yo)

    Non-Executive Chairman of the Board

    • Tenure: 8.7yrs
    • Compensation: US$102.41k
  • Bruce Huebner (68yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$47.66k
  • Lyle Arnold (72yo)

    Senior VP of R&D

    • Tenure: 0yrs
    • Compensation: US$287.43k
  • Claire Reiss

    Chairwoman Emeritus

    • Tenure: 8.6yrs
  • Marsha Chandler (74yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$39.91k
  • Fred Hirsch

    Member of Clinical Advisory Board

    • Tenure: 0yrs
  • Bruce Gerhardt (68yo)

    Independent Director

    • Tenure: 9.1yrs
    • Compensation: US$38.66k
  • Mike Nall (56yo)

    CEO, President & Director

    • Tenure: 6.3yrs
    • Compensation: US$439.72k

Company Information

Biocept, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biocept, Inc.
  • Ticker: B002
  • Exchange: DB
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$12.626m
  • Listing Market Cap: US$11.449m
  • Shares outstanding: 23.02m
  • Website: https://www.biocept.com

Number of Employees


Location

  • Biocept, Inc.
  • 5810 Nancy Ridge Drive
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOCNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2014
B002DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/22 22:43
End of Day Share Price2019/11/22 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.